Gilead Discontinues Development of Cicletanine

Dow Jones reported yesterday that Gilead Sciences have dropped the diuretic cicletanine after it failed to meet targets in a mid-stage clinical trial analysing the drug’s potential in high blood pressure. The Phase II, randomised, double-blind, placebo-controlled, multicenter, dose- ranging study was evaluating the efficacy, safety and tolerability of cicletanine in comparison to a placebo

Continue Reading

Boehringer Ingelheim and Gilead Sign Agreement for HIV Compound Rights

German corporation, Boehringer Ingelheim, and the Californian firm, Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has given Gilead exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase

Continue Reading